259 related articles for article (PubMed ID: 18790446)
1. Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
Bollard CM; Cooper LJ; Heslop HE
Best Pract Res Clin Haematol; 2008 Sep; 21(3):405-20. PubMed ID: 18790446
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
3. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.
Heslop HE
Hematology Am Soc Hematol Educ Program; 2005; ():260-6. PubMed ID: 16304390
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
Tatfi M; Hermine O; Suarez F
Front Immunol; 2018; 9():3060. PubMed ID: 30662441
[TBL] [Abstract][Full Text] [Related]
6. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
7. EBV-related lymphomas: new approaches to treatment.
Kanakry JA; Ambinder RF
Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
10. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
12. T-cell therapies for Epstein-Barr virus-associated lymphomas.
El-Bietar J; Bollard C
Pediatr Hematol Oncol; 2011 Nov; 28(8):627-39. PubMed ID: 22023461
[TBL] [Abstract][Full Text] [Related]
13. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
[TBL] [Abstract][Full Text] [Related]
14. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells and EBV associated malignancies.
Li J; Qian CN; Zeng YX
Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
18. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.
Rooney CM; Smith CA; Heslop HE
Mol Med Today; 1997 Jan; 3(1):24-30. PubMed ID: 9021739
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]